首頁 > 市場調查報告書 > 醫療設備

整形外科齒科設備植牙關節移植

市場調查報告書

商品編碼

1471989

生物植入物市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按類型、材料和最終用戶

Bio-Implants Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Material, and End User

出版日期: 2024年03月22日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

依據「2031 年生物植入物市場預測- COVID-19 影響和全球分析- 按類型、材料和最終用戶分類」的新研究，預計該市場將從2023 年的1178.2 億美元成長到2023 年的1178.2 億美元。預計 2023 年至 2031 年複合年成長率為 8.3%。市場成長歸因於生活方式障礙負擔的增加以及對微創外科手術的需求不斷成長。不斷成長的技術發展和政府舉措可能為生物植入市場提供成長機會。然而，產品召回和與植入材料相關的複雜性阻礙了生物植入市場的成長。

生物植入物是一種替代、增強或支撐生物結構的假體裝置。它們由多種生物合成成分組成，例如組織工程產品以及膠原蛋白，包括合成皮膚。醫療保健技術的發展促進了生物植入物市場的成長。儘管醫療保健行業多年來取得了顯著的技術進步，但嚴重疾病發病率的上升給生物植入物市場的成長帶來了各種挑戰。

2023年，北美佔據全球生物植入市場最大的市場佔有率。該地區生物植入物市場的成長得益於慢性病盛行率的不斷上升和醫療基礎設施的改善。 2022 年 7 月，美國疾病管制與預防中心 (CDC) 的最新資料顯示，冠狀動脈疾病是最常見的心臟病類型之一，在美國約有2010 萬20 歲及以上的成年人患有這種疾病。另外，根據CDC資料，美國每40秒就有一個人心臟病發作，即近80.5萬人。慢性病發病率的上升預計將增加對生物植入物的整體需求，從而推動預測期內的市場成長。預計 2023 年至 2031 年，亞太地區的生物植入市場複合年成長率最高。該地區的市場成長歸因於老年人口的成長、可支配收入的增加、醫療保健投資的增加和市場參與者的擴張，以及由於交通事故數量的增加而導致的脊髓損傷病例的增加。

不斷增加的技術發展和政府措施為未來提供市場機會

3D列印、雷射技術和奈米技術等技術發展顯著提高了生物植入物的生產。 3D 列印改變了生物植入物的設計和製造方法。該技術能夠創建具有複雜幾何形狀、精確尺寸和客製化功能的患者專用植入物，從而實現更好的貼合性和功能。此外，將感測器、微電子和無線通訊整合到植入物中有助於即時監測患者的狀況和健康狀況。智慧植入物可以將資料傳輸給醫療保健提供者，從而實現遠端監控和及時干預。

許多政府組織與進行健康研究和生產醫療設備的公司合作，以行銷新的、更有效的設備。例如，2023年12月，新加坡南洋理工大學與新加坡中央醫院（SGH）合作投資3D列印。該合作夥伴關係利用南洋理工大學新加坡 3D 列印中心和新加坡中央醫院 3D 列印中心的設施和綜合專業知識，研究和開發床邊臨床應用的相關技術。 2024 年 2 月，匹茲堡的一名工程師從美國國立衛生研究院獲得了 557,000 美元，用於開展世界上首次骨科超材料植入體內研究，以改善脊椎損傷的治療、修復和恢復。超材料比傳統元素、合金或其他材料更先進，因為它們可以設計成提供各種所需的機械性能，包括超輕、超硬、超高強度密度比、順應性和高彈性。此外，超材料植入物提供了很大的設計空間，因為它們可以由各種生物相容性材料製成。因此，預計不斷成長的技術發展和政府舉措將為預測期內的市場成長提供成長機會。

基於類型的見解

根據類型，生物植入物市場分為心血管植入物、骨科植入物、牙科植入物、眼科植入物等。心血管植入物細分市場在 2023 年佔據更大的市場佔有率。例如，2022 年 2 月，醫療技術公司雅培 (Abbott) 宣布全球首例患者植入無引線雙腔起搏器系統，作為其 AVEIR DR i2i 關鍵臨床試驗的一部分。雅培實驗性雙腔無引線心律調節器的植入代表了無引線心律調節器技術的一個重要技術里程碑；這是世界上第一個進行關鍵試驗的項目。

基於材料的見解

生物植入物市場依材料分為金屬、陶瓷和聚合物。金屬細分市場將在2023 年佔據最大的生物植入市場佔有率。大市場佔有率。例如，2021年12月，兩片式陶瓷植體先驅DentalPoint宣布其最新產品ZERAMEX XT已獲得美國FDA批准。該產品是美容假牙鈦植體的無金屬替代品，特別是在美容領域。

基於最終用戶的見解

根據最終用戶，市場分為醫院和診所以及門診手術中心。醫院和診所細分市場在 2023 年將佔據更大的生物植入市場佔有率，預計 2023 年至 2031 年期間複合年成長率將更高。

領先企業正在實施擴張、合作、推出新產品和獲取新客戶群等策略，以挖掘現有的商機。

2022年4月，骨科植入公司獲得食品藥物管理局批准，發布高瓣膜背側掃描板。該產品幫助擴大了該公司的骨科創傷產品組合，以實現 OIC 的 DRPx 手腕骨折電鍍系統的潛在臨床植入，從而鞏固其作為任何其他高價電鍍系統最全面和價值驅動的替代品之一的地位。

2022 年 1 月，強生醫療器材公司 (JJMDC) 與 Microsoft 合作，增強並進一步開發 JJMDC 安全、合規的數位手術生態系統。

2021 年10 月，ScottCare Cardioangio Solutions 與Ninety One Holding, Inc. 簽署協議，成為Ninety One 用於監測心臟植入設備的雲端軟體平台的主要分銷商，為兩家公司之間提供了有效的擴展合作夥伴關係。這使得 ScottCare Cardiological Solutions 能夠直接向診所提供 Ninety One 的雲端平台，讓診所與其員工一起監控和管理病患資料。 Ninety One 的軟體平台有助於將先進的資料科學與最新技術相結合，幫助分析和管理植入心臟設備的患者的複雜醫療資料。

美國食品藥物管理局、疾病管制與預防中心 (CDC) 以及全球疾病負擔研究是準備生物植入物市場報告時參考的主要和次要來源。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 13 章：生物植入物市場 - 主要公司概況

LifeNet Health
Smith & Nephew
Arthrex, Inc.
Clinic Lemanic
Alpha Bio Tec
MiMedx Group
Medtronic
St Jude Medical (Abbott)
Stryker Cooperation
DePuy Synthes
Biomet (Zimmer)
Exactech, Inc.
Cochlear Ltd
Straumann AG

第 14 章：附錄

簡介目錄

Product Code: TIPHE100001101

According to our new research study on "Bio-implants Market Forecast to 2031 - COVID-19 Impact and Global Analysis - by Type, Material, and End User," the market is anticipated to grow from US$ 117.82 billion in 2023 to US$ 223.06 billion by 2031; it is estimated to register a CAGR of 8.3% during 2023-2031. Market growth is attributed to the increasing burden of lifestyle disorders and the growing demand for minimally invasive surgical procedures. Increasing technological developments and government initiatives will likely provide growth opportunities for the bio-implants market. However, product recalls and complexities associated with implant materials hinder the growth of the bio-implants market.

Bio-implants are prosthetic devices that replace, enhance, or support a biological structure. They consist of several biosynthetic components, such as tissue engineering products, along with collagen, including synthetic skin. Technological development in healthcare has contributed to the growth of the bio-implants market. Although the healthcare sector has made significant technological advancements over the years, the rising incidence of serious medical diseases has led to various challenges to the growth of the market for bio-implants.

North America accounted for the largest market share of the global bio-implants market in 2023. The market in this region is segmented into the US, Canada, and Mexico. The growth of the bio-implants market in the region is due to the growing prevalence of chronic diseases and better healthcare infrastructure. In July 2022, updated Centers for Disease Control and Prevention (CDC) data shows that coronary artery disease is one of the most common types of heart diseases, with approximately 20.1 million adults aged 20 and older living with the disease in the US. Additionally, according to CDC data, every 40 seconds, an individual suffers from a heart attack in the US, i.e., nearly 805,000 people. The rising incidence of chronic diseases is expected to increase the overall demand for bio-implants, which is expected to boost the market growth during the forecast period. Asia Pacific is expected to register the highest CAGR in the bio-implants market during 2023-2031. The market growth in the region is ascribed to the growing geriatric population, increasing disposable income, rising healthcare investments and expansion by market players, and increasing cases of spinal cord injuries due to the rising number of traffic accidents.

Increasing Technological Developments and Government Initiatives to Provide Market Opportunities in the Future

Technological developments such as 3D printing, laser technology, and nanotechnology have significantly improved the production of bio-implants. 3D printing has transformed the designing and manufacturing methodologies of bio-implants. This technology enables the creation of patient-specific implants with intricate geometries, precise dimensions, and tailored features, resulting in better fit and functionality. Further, integrating sensors, microelectronics, and wireless communication into implants helps in the real-time monitoring of the patient's condition and health. Smart implants can transmit data to healthcare providers, enabling remote monitoring and timely interventions.

Many government organizations work with companies conducting health studies and producing medical devices to market new and more effective devices. For example, in December 2023, Nanyang Technological University Singapore and Singapore General Hospital (SGH) collaborated to invest in the advancement of 3D printing. The partnership leverages the facilities and combined expertise of the Singapore Center for 3D Printing at NTU and the 3D Printing Center at SGH to research and develop relevant technologies for clinical applications in point-of-care settings. In February 2024, a Pittsburgh engineer received US$ 557,000 from the National Institutes of Health to conduct the world's first in vivo studies of orthopedic metamaterial implants to improve spinal injuries' treatment, repair, and recovery. Metamaterials are more advanced than traditional elements, alloys, or other materials because they can be designed to provide a wide range of desired mechanical properties, including ultralight, ultra-stiff, ultrahigh strength-to-density ratios, compliance, and high resilience. In addition, metamaterial implants offer great scope for design as they can be made from various biocompatible materials. Thus, increasing technological developments and government initiatives are anticipated to provide growth opportunities for the market growth during the forecast period.

Type -Based Insights

Based on type, the bio-implants market is segmented into cardiovascular implants, orthopedic implants, dental implants, ophthalmic implants, and others. The cardiovascular implants segment held a larger market share in 2023. The growth of the segment is due to rapid rise in research and development activities to develop novel cardiac implant products. For example, in February 2022, Abbott, a medical technology company, announced the world's first patient implantation of a leadless dual-chamber pacemaker system as part of its AVEIR DR i2i pivotal clinical trial. The implantation of Abbott's experimental dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacemaker technology; it is the first in the world to be in a pivotal trial.

Material-Based Insights

The bio-implants market, based on material, is segmented into metals, ceramics, and polymers. The metals segment held the largest bio-implants market share in 2023. It is further expected to register the highest CAGR from 2023 to 2031. The ceramics segment is expected to hold the second-largest market share during the forecast period due to increasing approvals of ceramic products by regulatory authorities. For example, in December 2021, DentalPoint, the pioneer of two-piece ceramic implants, announced that it had received US FDA approval for its newest product, ZERAMEX XT. The product is a metal-free alternative to titanium implants for cosmetic dentures, especially in the aesthetic area.

End User-Based Insights

Based on the end user, the market is bifurcated into hospitals & clinics and ambulatory surgical centers. The hospitals & clinics segment held a larger bio-implants market share in 2023 and the same is anticipated to register a higher CAGR during 2023-2031.

Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.

In April 2022, Orthopedic Implant Company received approval from the Food and Drug Administration and released the high valve dorsal scanning plate. The product helped expand the company's orthopedic trauma portfolio for the potential clinical implantation of OIC's DRPx Wrist Fracture Plating System, reinforcing it as one of the most comprehensive and value-driven alternatives to any other premium-priced plating systems.

In January 2022, Johnson & Johnson Medical Devices Companies (JJMDC) collaborated with Microsoft to enhance and further develop JJMDC's secure and compliant digital surgery ecosystem.

In October 2021, ScottCare Cardiovascular Solutions signed an agreement with Ninety One Holding, Inc. to become the primary distributor for Ninety One's cloud software platform for monitoring cardiac implanted devices, providing an effective expansion partnership between the two companies. This allows ScottCare Cardiocular Solutions to offer Ninety One's cloud platform directly to clinics that work with their staff to monitor and manage patient data. Ninety One's software platform helps in combining advanced data science with the latest technologies to help analyze and manage complex medical data for patients with implanted cardiac devices.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study, are among the primary and secondary sources referred to while preparing the bio-implants market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Bio Implants Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Bio Implants Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Bio Implants Market - Global Market Analysis

6.1 Bio Implants - Global Market Overview
6.2 Bio Implants - Global Market and Forecast to 2031

7. Bio Implants Market - Revenue Analysis (USD Million) - By Type, 2021-2031

7.1 Overview
7.2 Cardiovascular Implants
7.3 Spinal Implants
7.4 Orthopedics Implants
7.5 Dental Implants
7.6 Ophthalmic Implants
7.7 Others

8. Bio Implants Market - Revenue Analysis (USD Million) - By Material, 2021-2031

8.1 Overview
8.2 Metal
8.3 Ceramics
8.4 Polymers

9. Bio Implants Market - Revenue Analysis (USD Million) - By End User, 2021-2031

9.1 Overview
9.2 Hospitals and Clinics
9.3 Ambulatory Surgical Centers

10. Bio Implants Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

10.1 North America
- 10.1.1 North America Bio Implants Market Overview
- 10.1.2 North America Bio Implants Market Revenue and Forecasts to 2031
- 10.1.3 North America Bio Implants Market Revenue and Forecasts and Analysis - By Type
- 10.1.4 North America Bio Implants Market Revenue and Forecasts and Analysis - By Material
- 10.1.5 North America Bio Implants Market Revenue and Forecasts and Analysis - By End User
- 10.1.6 North America Bio Implants Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Bio Implants Market
    - 10.1.6.1.1 United States Bio Implants Market, by Type
    - 10.1.6.1.2 United States Bio Implants Market, by Material
    - 10.1.6.1.3 United States Bio Implants Market, by End User
  - 10.1.6.2 Canada Bio Implants Market
    - 10.1.6.2.1 Canada Bio Implants Market, by Type
    - 10.1.6.2.2 Canada Bio Implants Market, by Material
    - 10.1.6.2.3 Canada Bio Implants Market, by End User
  - 10.1.6.3 Mexico Bio Implants Market
    - 10.1.6.3.1 Mexico Bio Implants Market, by Type
    - 10.1.6.3.2 Mexico Bio Implants Market, by Material
    - 10.1.6.3.3 Mexico Bio Implants Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Bio Implants Market - Key Company Profiles

13.1 LifeNet Health
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies